Alcatel-Lucent (Paris: ALU) is again seeking buyers for its enterprise business, according to Reuters. The company explored such a sale in 2011 but didn’t find buyers, instead selling only part of the unit (Genesys) to Permira for $1.5 billion. Lazard is managing the new process. www.alcatel-lucent.com
John Wood Group PLC (LSE: WG) has agreed to acquire Elkhorn Holdings Inc., a Wyoming-based provider of infrastructure construction and maintenance services to the U.S. energy market. No financial terms were disclosed. Deloitte Corporate Finance managed the process.www.woodgroup.com
Mitel Networks Corp. (Nasdaq: MITL) has agreed to acquire Aastra Technologies Ltd. (TSX: AAH), a Canadian provider of enterprise communication solutions, for C$392 million in cash and stock (represents a 13% premium to Friday’s closing price for Aastra stock). www.mitel.com
Novartis (Swiss: NOVN) has agreed to sell its blood transfusion diagnostics unit to Spain’s Grifols(CATS: GRF) for $1.675 billion. The deal is expected to close in the first half of 2014, pending regulatory approval. www.grifols.com
Shire PLC (LSE: SHP) has agreed to acquire Exton, Penn.-based drugmaker ViroPharma Inc.(Nasdaq: VPHM) for $4.2 billion in cash, or $50 per share (27% premium to Friday’s closing price).www.viropharma.com
Vox Media, publisher of content sites like The Verge (tech) and SB Nation (sports), has agreed to acquire Curbed Network, a group of urban lifestyle and entertainment blogs. Fortune reports that the deal is structured as a mix of cash and stock valued at between $20 million and $30 million. Vox Media has raised over $60 million from Accel Growth Fund, Accel Partners, Khosla Ventures and Comcast Ventures. Read more.
Bain Capital has filed to sell 7.49 million shares in child care center operator Bright Horizons Family Solutions (NYSE: BFAM), which would lower its ownership stake from 64.3% to 52.8%. Bright Horizons went public in January at $22 per share, and closed trading Friday at $36.38 per share. This would be Bain’s second share sale since the IPO, having previously sold 8.5 million shares over the summer. www.brighthorizons.com
Deutsche Telekom has acquired GTS (DB: DTE), an infrastructure-based telecom service provider in Southeast and Eastern Europe, for €546 million. Sellers include Bessemer Venture Partners, Columbia Capital, HarbourVest Partners, Innova Capital, MC Partners and Oak Investment Partners.www.telekom.com
Crestview Partners has canceled the auction Munder Capital Management after failing to secure adequate bids, according to peHUB. Crestview had been seeking between $350 million and $400 million for the Michigan-based asset management firm, with Goldman Sachs managing the process.www.munder.com
Essilor International (Paris: EI) has agreed to acquire Costa Inc. (Nasdaq: ATX), a Lincoln, R.I.-based maker of branded sunglasses, for $270 million in cash, or $21.50 per Costa share (7.6% premium to yesterday’s closing price). www.essilor.com
Macquarie Group is planning to offer approximately $800 million in cash to acquire the Scottish Windows asset management unit of Lloyds Banking Group, according to the WSJ.www.macquarie.com
Salix Pharmaceuticals Ltd. (Nasdaq: SLXP) has agreed to acquire San Diego-based drugmakerSantarus Inc. (Nasdaq: SNTS) for approximately $2.6 billion in cash, or $32 per Santarus share (36% premium to Wednesday’s closing price). www.salix.com
Standard Bank (JSE: SBK) of South Africa said that it is in talks to sell a controlling stake in its non-Africa global markets business. www.standardbank.co.za
Talisman Energy Inc. (TSX: TLM) has agreed to sell around three-quarters of its stake in the Montney oil field in British Columbia to Progress Energy Canada Ltd. for C$1.5 billion in cash. It is part of Talisman’s plan to generate around $3 billion from asset sales this year. www.talisman-energy.com
Amedica Corp., a Salt Lake City-based maker of spine and reconstructive surgery implants and instruments, has filed for a $35 million IPO. It plans to trade on the Nasdaq under ticker symbol AMDA, with JMP Securities listed as lead underwriter. The company reports a $6.4 million net loss on $11.3 million in revenue for the first half of 2013. www.amedica.com
Cara Therapeutics, a Shelton Conn.-based developer of therapeutics for treating pain, has filed for a $60 million IPO. It plans to trade on the Nasdaq under ticker symbol CARA, with Stifel and Piper Jaffray serving as lead underwriters. Shareholders include Rho Ventures (14.5% pre-IPO stake), Alta Partners (10.7%), Ascent Biomedical Ventures (9.9%), MVM (9.7%), Devon Park Bioventures (9.4%), Esperante AB (9.2%) and Scottish Widows (5.3%). www.caratherapeutics.com
Globoforce Ltd., a provider of cloud-based social recognition software for organizations use to engage their employees, has filed for a $75 million IPO. It plans to trade on the Nasdaq under ticker symbol THNX, with J.P. Morgan listed as left lead underwriter. The company reports a $3 million net loss on $84 million in revenue for the first half of 2013. Shareholders include Balderton Capital (41.5% pre-IPO stake) and Atlas Venture (31.4%). The company is based in Ireland, with U.S. offices in Southborough, Mass. www.globoforce.com
Scorpio Bulkers Inc., a Monaco-based operator of dry freight carrying fleets, has filed for a $100 million IPO. It plans to trade on the NYSE under ticker symbol SALT, with Deutsche Bank Securities listed as lead underwriter. It already trades on the Norwegian OTC List. www.scorpiobulkers.com
Ultragenyx Pharmaceutical Inc., a Novato, Calif..-based developer of rare disease therapeutics, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol RARE, with J.P. Morgan and Morgan Stanley serving as lead underwriters. Shareholders in the pre-revenue company include TPG Biotech (13.2% pre-IPO stake), Beacon Bioventures (13.2%), HealthCap (11.8%), Adage Capital Partners (7.4%), Capital Research Global Investors (6.4%) and Pappas Ventures (5.9%).www.ultragenyx.com
GlycoMimetics, a Gaithersburg, Md.-based developer of glycobiology-based therapies, has postponed an IPO that had been scheduled to price this week. This company plans to offer 4 million shares at between $14 and $16 per share, and trade on the Nasdaq under ticker symbol GLYC. Jefferies and Barclays are serving as lead underwriters. Glycomimetics has raised over $60 million in VC funding from firms like New Enterprise Associates (75.2% pre-IPO stake), Genzyme Ventures (11.6%), The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures. www.glycomimetics.com
Sign up for Dan’s daily email newsletter on deals and deal-makers: GetTermSheet.com
